Human papillomavirus type 11 E2 protein transactivation domain (HPV11 E2 TAD)

The Human Papillomavirus type 11 (HPV11) E2 protein transactivation domain (TAD) is a conserved N-terminal region of approximately 200 amino acids that plays a central role in the viral life cycle (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114497/). It is responsible for recruiting the viral E1 helicase to the origin of replication, a step that is essential for the initiation of viral DNA synthesis (https://pubmed.ncbi.nlm.nih.gov/14759295/). Beyond replication, the TAD also functions as a transcriptional regulator by interacting with cellular co-activators and the basal transcription machinery to modulate the expression of viral genes (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230246/). This domain also facilitates the tethering of the viral genome to host chromosomes during mitosis, ensuring the maintenance of the viral episome in dividing cells (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC114497/). Due to its critical role in both replication and transcription, the HPV11 E2 TAD has emerged as a significant therapeutic target for antiviral drug development (https://pubmed.ncbi.nlm.nih.gov/14759295/). Small molecule inhibitors, such as those in the indandione and repaglinide-like classes, have been identified that bind to the TAD and disrupt its interaction with E1 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230246/). These inhibitors effectively block viral DNA replication in cellular assays and represent a promising strategy for treating low-risk HPV infections like genital warts and recurrent respiratory papillomatosis (https://pubmed.ncbi.nlm.nih.gov/14759295/). Therapeutic challenges include achieving high selectivity for specific HPV types and overcoming the inherent difficulty of targeting protein-protein interaction interfaces (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230246/). Additionally, some inhibitor classes have shown off-target effects, such as hypoglycemia in the case of repaglinide-like compounds, which complicates clinical development (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230246/).

Other names

HPV11 E2 transactivation domainHPV11 E2 activation domainHPV11 E2-TADHuman papillomavirus type 11 E2 N-terminal domain

Inhibition of E1-E2 protein-protein interaction